Redeye returns with an updated take on NextCell following the inconclusive interim analysis, which has led to a sharp decline in the share p...
Redeye comments on the preliminary one-year results from the ProTrans-Young trial, announced by NextCell yesterday after market close ahead ...
Redeye comments on NextCell Pharma ahead of the upcoming interim data from ProTrans-Young, set to be presented in connection with the IDF Wo...
Redeye leaves a short comment on yesterday's announcement that all patients in the ProTrans V study have been treated.
Redeye initiates coverage of NextCell Pharma, a clinical-stage biotech company developing a cell therapy with disease-modifying potential in...
